Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 16/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19776224 | 0.83 | CA2 (0.54) | FFAR1L3MBTL1MAPK1MTNR1A | |
| SCHEMBL19776040 | 0.83 | CA2 (0.54) | FFAR1L3MBTL1MAPK1MTNR1A | |
| SCHEMBL19776284 | 0.82 | DRD2 (0.54) | FFAR1L3MBTL1MAPK1MTNR1A | |
| SCHEMBL19776654 | 0.82 | DRD2 (0.54) | FFAR1L3MBTL1MAPK1MTNR1A | |
| SCHEMBL19776291 | 0.82 | FFAR1 (0.54) | FFAR1L3MBTL1MAPK1MTNR1ACYP2C9 | |
| SCHEMBL19776202 | 0.82 | FFAR1 (0.54) | FFAR1L3MBTL1MAPK1MTNR1ACYP2C9 | |
| SCHEMBL6740016 | 0.81 | FFAR1 (0.51) | FFAR1MTNR1ACYP2C9CYP2B6SLCO1B3 | |
| SCHEMBL6738922 | 0.81 | FFAR1 (0.49) | FFAR1L3MBTL1 | |
| SCHEMBL15865348 | 0.81 | FFAR1 (0.49) | FFAR1L3MBTL1 | |
| SCHEMBL15865467 | 0.81 | FFAR1 (0.49) | FFAR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145634-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-05-08 | — | — | US | disclosed |
| US-20240058340-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | ERASCA, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | disclosed |
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | disclosed |
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | disclosed |
| CN-115215808-A | Compositions and methods for treating cancer | 加利福尼亚大学董事会 | 2022-10-21 | — | — | CN | disclosed |
| US-11377451-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-05 | — | — | US | disclosed |
| US-11377451-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-05 | — | — | US | disclosed |
| WO-2022061202-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-24 | — | — | WO | disclosed |
| WO-2022061202-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-24 | — | — | WO | disclosed |
| WO-2022061201-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
| CN-113811528-A | Compositions and methods for treating cancer | 加利福尼亚大学董事会 | 2021-12-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145634-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, SLC2A1, EGFR | FFAR1 2846/4885L3MBTL1 3738/4885MAPK1 1392/4885 |
| US-11377451-B2 | Compositions and methods for treating cancer | TP53, EGFR, SLC2A1 | FFAR1 3500/4885L3MBTL1 3700/4885MAPK1 1416/4885 |
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, EGFR, SLC2A1 | FFAR1 3096/4885L3MBTL1 3803/4885MAPK1 1531/4885 |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, SLC2A1, EGFR | FFAR1 2846/4885L3MBTL1 3738/4885MAPK1 1392/4885 |
| US-20240058340-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, EGFR, SLC2A1 | FFAR1 3096/4885L3MBTL1 3803/4885MAPK1 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.